Tranexamic Acid Dose Conversion: Weekly to Daily for Heavy Menstrual Bleeding

What "Weekly vs. Daily" Actually Means for Tranexamic Acid

Tranexamic acid is not taken every day of the month. That distinction matters enormously, because most women who search for a "weekly to daily conversion" are either switching from an intermittent low-frequency schedule their provider started them on, or they are converting a dosing instruction written in tablets per week into a per-day figure they can follow on a calendar.

The US FDA-approved label for Lysteda specifies 1,300 mg orally three times daily for up to 5 days during menstruation only. That works out to 3,900 mg on each bleeding day, and a maximum of 19,500 mg per cycle. There is no approved once-weekly or twice-weekly regimen for heavy menstrual bleeding (HMB) in the United States.

Where the "Weekly Dose" Concept Comes From

Two situations create the weekly-to-daily confusion:

1. UK and international prescribing. The British National Formulary has historically listed tranexamic acid as 1 g (1,000 mg) three to four times daily for up to 4 days, with some guidance documents expressing that total as a "per-period course" rather than a per-day instruction. Women reading UK resources alongside US resources encounter different framing.

2. Off-label titration in practice. Some women's-health clinicians start patients at a lower dose, such as 650 mg (one tablet) three times daily, and step up to the full 1,300 mg three times daily after one cycle if bleeding control is insufficient. When that titration schedule is written as a "week 1 dose" and a "week 2-onward dose," it reads like a weekly-to-daily conversion even though both regimens are still day-of-bleeding-only dosing.

The Practical Conversion Table

| Schedule label | What you actually take | Total per bleeding day | Notes | |---|---|---|---| | "Starting dose" (off-label titration) | 650 mg three times daily | 1,950 mg | One 650 mg tablet per dose | | Full approved dose | 1,300 mg three times daily | 3,900 mg | Two 650 mg tablets per dose | | UK standard (per BNF guidance) | 1,000 mg three to four times daily | 3,000-4,000 mg | 500 mg tablets used in UK | | Maximum approved duration | 5 days per cycle | 19,500 mg per cycle | Do not extend without specialist review |

How Tranexamic Acid Works and Why Women's Physiology Matters

Tranexamic acid is a synthetic lysine analog that blocks plasminogen from binding to fibrin, slowing clot breakdown (fibrinolysis). During a normal menstrual period, the endometrium releases high concentrations of tissue plasminogen activator (tPA), which dissolves clots and allows the uterine lining to shed. In women with HMB, endometrial tPA activity is significantly elevated compared to women with normal flow, which is why antifibrinolytics are mechanistically well-suited to this condition.

The Menstrual Cycle Changes Drug Need

You only need tranexamic acid on days when fibrinolysis is actively breaking down endometrial clots. Taking it outside of bleeding days provides no benefit for HMB and unnecessarily extends systemic antifibrinolytic exposure. This is why the dosing is cycle-timed, not continuous.

The amount of endometrial tPA activity, and therefore the degree of excessive fibrinolysis, tracks with estrogen exposure across life stages:

• Reproductive years with regular cycles: tPA peaks at the start of menstruation; standard 5-day course covers the highest-risk window.
• Perimenopause: Anovulatory cycles produce prolonged, unopposed estrogen stimulation of the endometrium, which can make periods heavier and more prolonged. The 5-day cap may not cover an 8-day bleed; a clinician must decide whether extending past day 5 (off-label) is appropriate or whether adding a progestogen is a better choice.
• PCOS: Irregular, often anovulatory cycles mean HMB episodes are unpredictable. Tranexamic acid taken at the onset of each bleed is practical precisely because it does not require cycle-day predictability, unlike NSAIDs timed to day 1.

What the THER-501 Trial Found for Women

The key US registration trial (THER-501) enrolled 187 women with objectively confirmed HMB (menstrual blood loss greater than 80 mL per cycle by alkaline hematin method). Women randomized to tranexamic acid 1,300 mg three times daily for 5 days had a mean reduction in menstrual blood loss of 40.4% versus 8.2% for placebo, a difference that was statistically significant (p < 0.001). The trial ran for three treatment cycles, so the 40% reduction figure reflects sustained, not single-cycle, benefit.

No trial has formally compared the 650 mg three-times-daily starting dose against 1,300 mg three-times-daily in a head-to-head RCT within the US. The dose-titration recommendation therefore rests on pharmacokinetic modeling and clinical practice rather than direct randomized evidence. That evidence gap matters, and you deserve to know it.

Step-by-Step Dose Conversion: From a Weekly Schedule to a Per-Day Instruction

If your provider wrote your prescription as a number of tablets per week, or if you received dosing written around "the first week of the cycle," here is how to translate that into a day-by-day schedule.

Step 1: Identify Your Total Tablet Count per Course

Count the total number of 650 mg tablets listed for one menstrual period. A full approved course is 30 tablets (two tablets, three times daily, for 5 days). A half-dose titration course is 15 tablets (one tablet, three times daily, for 5 days).

Step 2: Divide by the Number of Bleeding Days You Will Cover

The label caps the course at 5 days. If your provider wrote a 5-day course:

• 30 tablets over 5 days = 6 tablets per day (2 tablets per dose, 3 doses per day)
• 15 tablets over 5 days = 3 tablets per day (1 tablet per dose, 3 doses per day)

Step 3: Set Your Dosing Clock

Space doses 6 to 8 hours apart. A practical schedule for most women is with breakfast, with lunch, and with the evening meal. Taking each dose with food reduces the incidence of nausea, which affects approximately 19% of women on tranexamic acid in clinical trials compared with 15% on placebo.

Step 4: Start on Day 1 of Bleeding, Not Day 1 of Your Cycle

"Day 1 of your cycle" and "day 1 of bleeding" are the same event for most women, but women with spotting before full flow sometimes count spotting days as day 1. Tranexamic acid should start when active bleeding begins, not during spotting.

The WomanRx Titration Framework: When to Use the Half-Dose Start

This framework is used in WomanRx clinical practice for selecting a starting dose. It is not derived from a published guideline; it reflects our editorial board's consensus based on the available pharmacokinetic and safety literature.

Start at 650 mg three times daily (half-dose) if any of the following apply:

• First cycle using tranexamic acid (tolerability assessment)
• History of nausea or GI sensitivity to medications
• Body weight below 55 kg (pharmacokinetic data show higher plasma concentrations per kg at lower weights, though a formal weight-based dose-adjustment table does not exist in the label)
• Concurrent SSRI or SNRI use (serotonin syndrome risk is theoretical but warrants monitoring given combined effects on platelet function)

Step up to 1,300 mg three times daily at cycle 2 if:

• Bleeding reduction was less than 25% by patient self-assessment
• No intolerable GI side effects occurred at the lower dose
• No new thrombotic risk factors appeared

Remain at 650 mg three times daily long-term if:

• Bleeding reduction of 25% or more is achieved and acceptable to you
• Tolerability at the higher dose was a concern in cycle 1

Who This Drug Is Right For, and Who It Is Not

Women Who Benefit Most

Tranexamic acid sits in a specific clinical niche: non-hormonal management of HMB in women who want to preserve ovulatory function or avoid systemic hormones. ACOG Practice Bulletin No. 236 on abnormal uterine bleeding identifies tranexamic acid as an appropriate medical option for HMB associated with ovulatory dysfunction, including PCOS.

Women who are most likely to benefit:

• Reproductive-age women with objectively heavy periods who are not trying to conceive and do not need contraception
• Women with PCOS who have irregular, heavy bleeds and want a non-hormonal option
• Perimenopausal women with anovulatory HMB who cannot or prefer not to use hormonal therapy
• Women who have had inadequate response to NSAIDs alone (ibuprofen, mefenamic acid) for HMB

Women Who Should Not Use It

Tranexamic acid is not appropriate for everyone. Avoid it if you have:

• A personal history of deep vein thrombosis, pulmonary embolism, or retinal vein occlusion. The drug's antifibrinolytic mechanism theoretically raises clot risk, and the FDA label carries a contraindication for active thromboembolic disease.
• A known thrombophilia (factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome) without specialist clearance.
• Concurrent use of combined hormonal contraception (estrogen-containing pills, patch, or ring). The combination raises thrombotic risk, and most guidelines advise against concurrent use.
• Subarachnoid hemorrhage (a separate indication in other settings; here the dosing context differs entirely).
• Irregular bleeding that has not been evaluated by pelvic ultrasound or endometrial biopsy. Tranexamic acid treats a symptom; it does not diagnose or treat structural causes like fibroids, polyps, or endometrial hyperplasia. Treat the symptom only after ruling out serious pathology.

Life-Stage Guide: How Dosing and Decisions Differ

Reproductive Years (Ages 18-40, Regular Cycles)

This is the population studied in THER-501. The 1,300 mg three-times-daily regimen for 5 days is appropriate after ruling out structural pathology. Tranexamic acid does not affect ovulation, does not thin the uterine lining over time, and does not interact with fertility. A Cochrane systematic review confirmed that antifibrinolytics reduce HMB more effectively than placebo and are at least as effective as NSAIDs, which supports its use as a first-line non-hormonal option.

Trying to Conceive

Stop tranexamic acid before or at confirmed ovulation if you are actively trying to conceive in a given cycle, since it would then be used during a potential implantation window. There are no data on embryo toxicity from brief cycle-timed exposure at this stage, but avoiding any unnecessary drug exposure during a conception cycle is standard clinical caution.

Perimenopause (Typical Age Range 45-52)

HMB is one of the most common and new symptoms of perimenopause. Estrogen fluctuation, anovulatory cycles, and fibroids (which peak in prevalence in the late 40s) all converge to make periods heavier. Tranexamic acid addresses the fibrinolytic component of HMB without suppressing the ovarian hormonal fluctuations that characterize perimenopause, meaning it will not worsen vasomotor symptoms or alter the hormone trajectory of this transition. A practical note: perimenopausal bleeds are often unpredictable in start date. Keep your supply on hand and begin dosing at the first sign of active flow.

Post-Menopause

Any uterine bleeding after 12 consecutive months of amenorrhea must be evaluated before attributing it to a benign cause. Tranexamic acid is not appropriate for managing post-menopausal bleeding without a prior workup that excludes endometrial cancer or hyperplasia.

Pregnancy, Lactation, and Contraception

This section is mandatory reading if you are pregnant, breastfeeding, or might become pregnant.

Pregnancy

Tranexamic acid crosses the placenta. Animal reproductive studies have not demonstrated teratogenicity, which places it in FDA Pregnancy Category B. However, the approved indication for HMB is an elective use, and the benefit-risk calculation for elective treatment shifts significantly during pregnancy. Tranexamic acid should not be used for elective management of HMB during pregnancy.

A separate high-dose intravenous formulation of tranexamic acid is used under specialist supervision for obstetric hemorrhage (postpartum hemorrhage, placenta previa bleeding). The WOMAN trial (2017) in The Lancet showed that early IV tranexamic acid reduced death due to bleeding in postpartum hemorrhage by 19% when given within 3 hours of delivery. That is an acute, life-threatening, hospital-administered use, entirely distinct from the oral Lysteda tablets discussed in this article.

Oral tranexamic acid for routine HMB is contraindicated during pregnancy. If you discover you are pregnant while taking it for HMB, stop the medication and contact your provider.

Lactation

Tranexamic acid is excreted into breast milk at approximately 1% of the maternal serum concentration, which is a very low level. The American Academy of Pediatrics has historically classified it as compatible with breastfeeding based on this low transfer. The LactMed database (NIH) lists no adverse infant effects reported at this exposure level. Postpartum women with HMB who are breastfeeding may use oral tranexamic acid after discussing the low but non-zero exposure with their provider.

Contraception Requirements

Tranexamic acid is not a contraceptive and has no hormonal activity. It does not prevent pregnancy. The contraception consideration here runs in the opposite direction: combined hormonal contraceptives (estrogen-containing) raise venous thromboembolism risk, and adding an antifibrinolytic to that background risk is generally avoided. If you need both contraception and HMB treatment, progesterone-only methods (the levonorgestrel IUD, the progestin-only pill, the implant, or depot medroxyprogesterone) are preferred over combined hormonal methods when tranexamic acid is part of the plan. The levonorgestrel 52 mg IUD (Mirena) both prevents pregnancy and reduces HMB by approximately 71-96% by 12 months, which often makes tranexamic acid unnecessary for women who choose that option.

Side Effects and What to Watch For

The most common side effects at the therapeutic dose are gastrointestinal: nausea, vomiting, and diarrhea. These affect roughly 1 in 5 women (19% nausea rate in THER-501) and are dose-related, which is one reason the titration approach starting at 650 mg is used in practice.

Less common but more serious concerns include:

• Visual disturbances. Retinal artery and vein occlusion have been reported rarely. Stop the drug and seek same-day ophthalmology evaluation if you notice sudden changes in vision, color perception, or visual field.
• Allergic reactions. Skin rash, anaphylaxis. Rare.
• Thromboembolic events. The absolute risk increase in the absence of pre-existing thrombotic risk factors appears to be low in the RCT data, but the theoretical concern is real. Report leg swelling, chest pain, or shortness of breath immediately.

Drug Interactions Relevant to Women

Two interactions deserve specific attention for women:

1. Combined hormonal contraceptives. As described above, the estrogen component raises VTE risk. The FDA label notes this combination should be used cautiously if at all. Most clinicians advise against it.

2. Factor IX complex concentrates and anti-inhibitor coagulant concentrates. These are clotting factor products used in hemophilia. Women with bleeding disorders who are on factor replacement should discuss tranexamic acid use with a hematologist, as the combination can increase thrombosis risk.

3. Tretinoin (all-trans retinoic acid). This is a less commonly discussed interaction, but tretinoin (used in APML and in high-dose dermatologic contexts) inhibits fibrinolysis through a separate pathway; combining it with tranexamic acid is generally avoided in oncology settings. For most women using low-dose topical tretinoin for acne or anti-aging, systemic absorption is too low for this to be clinically relevant.

Practical Checklist Before Your First Cycle

Use this checklist to confirm you are ready to start your first course:

• Pelvic ultrasound and, if indicated, endometrial biopsy completed to exclude structural pathology
• Personal and family history of blood clots discussed with your provider
• Current contraceptive method reviewed (no combined estrogen-containing method while on tranexamic acid unless individually risk-assessed)
• Starting dose confirmed: 650 mg three times daily (titration start) or 1,300 mg three times daily (full dose)
• Supply on hand before period is expected: 15 tablets minimum for half-dose course, 30 tablets for full-dose course
• Know your stop criteria: vision changes, limb swelling, chest pain, breathing difficulty mean stop immediately and seek care